Product image of Mirtazapin Krka (Mirtazapine) supplied by GNH India

Mirtazapin Krka

Active Ingredient:
Mirtazapine
Origin:
EU

Mirtazapin Krka (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Krka, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adults and works by modulating norepinephrine and serotonin pathways to improve mood and sleep.

GNH India supplies Mirtazapin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory documentation and consistent quality for global mental‑health treatment programs and compliance with international standards.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirtazapine is used primarily in the treatment of depressive disorders, targeting mood regulation and associated symptoms.

  • Major depressive disorder: reduces core depressive symptoms such as low mood, loss of interest, and improves overall functional outcomes.
  • Depression with anxiety features: alleviates both depressive mood and concurrent anxiety symptoms, leading to better patient comfort and daily functioning.
  • Insomnia associated with depression: promotes sleep onset and maintenance, helping restore normal sleep patterns and reduce fatigue.

How It Works

  • Mirtazapine acts as an antagonist at central presynaptic α2‑adrenergic receptors, increasing the release of norepinephrine and serotonin. It also blocks postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic transmission while reducing related side effects, and antagonizes histamine H1 receptors, contributing to its sedative properties. Additionally, the drug’s antagonism at 5‑HT2C receptors may further increase dopaminergic activity in certain brain regions, supporting its antidepressant effect.

Side Effects

Mirtazapine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Sedation or drowsiness
  • Increased appetite and weight gain
  • Dry mouth
  • Constipation

Serious or Rare Side Effects

  • Agranulocytosis (rare blood disorder)
  • Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)
  • Suicidal thoughts or behavior, especially early in treatment.

Precautions & Warnings

When prescribing mirtazapine, clinicians should consider several safety precautions to minimize risks.

  • Monitor hepatic function: assess liver enzymes before and during therapy in patients with liver disease.
  • Assess for suicidal ideation: closely observe patients, especially during the initial treatment period.
  • Use cautiously in the elderly: increased sensitivity to sedation and anticholinergic effects.
  • Avoid abrupt discontinuation: taper the dose gradually to reduce withdrawal symptoms.
  • Store at room temperature: keep in the original pack, protect from moisture and light.

Avoid Interactions

Mirtazapine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis or serotonin syndrome.
  • Potent CYP3A4 inhibitors (e.g., ketoconazole): can markedly increase mirtazapine plasma concentrations.

Moderate Interactions (Monitor Closely)

  • CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation and respiratory depression.
  • Other serotonergic agents (e.g., SSRIs, SNRIs): increase risk of serotonin syndrome, requiring dose adjustments.
  • Anticholinergic drugs: additive effects on dry mouth and constipation.

Frequently Asked Questions

Mirtazapin Krka contains mirtazapine, which is prescribed to treat major depressive disorder in adult patients. It helps alleviate core depressive symptoms such as low mood, loss of interest, and associated anxiety or sleep disturbances.

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing norepinephrine and serotonin release. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors and histamine H1 receptors, enhancing serotonergic activity while providing a sedative effect that can improve sleep.

The appropriate dose of Mirtazapin Krka is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. No fixed regimen is provided here; the prescriber sets the specific dosage and titration schedule.

Safety data for mirtazapine in pregnancy and lactation are limited, and the product’s pregnancy category is unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined noradrenergic and serotonergic activity and strong antihistamine effect. This profile often results in greater sedation and appetite increase, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those needing an activating agent.

Mirtazapin Krka should be stored at room temperature, below 25 °C, in the original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat to maintain product stability.

The medication is taken orally, usually once daily in the evening due to its sedative properties. Patients should swallow the tablet whole with water and follow the prescribing clinician’s instructions regarding timing and food intake.

Serious risks include rare blood disorders such as agranulocytosis, severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome), and the emergence or worsening of suicidal thoughts, particularly during the early weeks of therapy. Prompt medical attention is required if any of these events occur.

Patients with known hypersensitivity to mirtazapine or any of its excipients should avoid the product. Caution is also advised for individuals taking MAO inhibitors, those with uncontrolled severe liver disease, or patients at high risk for suicidal behavior; a clinician must evaluate suitability.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.